Most importantly, the immunotherapy based on CD47 down-regulation may raise a concern about anemia because red blood cells also evade the macrophage phagocytosis response by high-expressed CD47, and the severe anemia caused by CD47 ICB therapy become a crucial issue for clinical usage in patients. Here, CD47 is linked to anemia.